2023
Assessment of proxy‐reported responses as predictors of motor and sensory peripheral neuropathy in children with B‐lymphoblastic leukemia
Rodwin R, DelRocco N, Hibbitts E, Devidas M, Whitley M, Mohrmann C, Schore R, Raetz E, Winick N, Hunger S, Loh M, Hockenberry M, Ma X, Angiolillo A, Ness K, Kairalla J, Kadan‐Lottick N. Assessment of proxy‐reported responses as predictors of motor and sensory peripheral neuropathy in children with B‐lymphoblastic leukemia. Pediatric Blood & Cancer 2023, 70: e30634. PMID: 37592363, PMCID: PMC10552080, DOI: 10.1002/pbc.30634.Peer-Reviewed Original ResearchConceptsChemotherapy-induced peripheral neuropathyPeripheral neuropathyLymphoblastic leukemiaPediatric Outcomes Data Collection InstrumentPT/OTSensory peripheral neuropathyAcute lymphoblastic leukemiaPredictor of motorProxy-report measuresCommon conditionOccupational therapistsNeuropathyChildrenLeukemiaFunction studiesResponse
2017
Cost‐effectiveness analysis of consolidation with brentuximab vedotin for high‐risk Hodgkin lymphoma after autologous stem cell transplantation
Hui L, von Keudell G, Wang R, Zeidan AM, Gore SD, Ma X, Davidoff AJ, Huntington SF. Cost‐effectiveness analysis of consolidation with brentuximab vedotin for high‐risk Hodgkin lymphoma after autologous stem cell transplantation. Cancer 2017, 123: 3763-3771. PMID: 28640385, PMCID: PMC5610636, DOI: 10.1002/cncr.30818.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsIncremental cost-effectiveness ratioPrice reductionHealth care costsProbabilistic sensitivity analysesMarkov decision-analytic modelCost-effectiveness ratioIndication-specific pricingLife-time costsCare costsAutologous stem cell transplantationDecision analytic modelStandard discountingQALYBrentuximab vedotinHigher health care costsActive surveillancePricingConsolidative settingConsolidation therapyCostSensitivity analysis
2016
Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study
Steensma DP, Abedi M, Bejar R, Cogle CR, Foucar K, Garcia-Manero G, George TI, Grinblatt D, Komrokji R, Ma X, Maciejewski J, Pollyea DA, Savona MR, Scott B, Sekeres MA, Thompson MA, Swern AS, Nifenecker M, Sugrue MM, Erba H. Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study. BMC Cancer 2016, 16: 652. PMID: 27538433, PMCID: PMC4991094, DOI: 10.1186/s12885-016-2710-6.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaObservational cohort studyDisease RegistryCohort studyClinical outcomesPatient-reported health-related qualityProspective observational cohort studyBaseline patient characteristicsHigh-risk MDSHealth-related qualityNon-interventional studyPatient-reported outcomesLower-risk MDSHealth economic outcomesMinimal diagnostic criteriaRoutine clinical settingNatural history studiesBackgroundMyelodysplastic syndromesPersistent cytopeniasOlder patientsPatient characteristicsTreatment patternsAlternate diagnosisCentral reviewMyelodysplastic syndromeAssociation between Time since Cancer Diagnosis and Health-Related Quality of Life: A Population-Level Analysis
Wang SY, Hsu SH, Gross CP, Sanft T, Davidoff AJ, Ma X, Yu JB. Association between Time since Cancer Diagnosis and Health-Related Quality of Life: A Population-Level Analysis. Value In Health 2016, 19: 631-638. PMID: 27565280, PMCID: PMC5002308, DOI: 10.1016/j.jval.2016.02.010.Peer-Reviewed Original ResearchConceptsComponent summary scoresSF-6D scoresMental component summary scoresSurvivors of prostateYear of diagnosisPoor-prognosis cancerCancer survivorsSummary scoresCancer diagnosisCervical cancerLower mental component summary scoresLower SF-6D scoresPhysical component summary scoreCancer typesSurvivors of breastHealth-related qualityLevel of HRQoLPatient demographic characteristicsBreast cancer survivorsDecade of diagnosisDemographic characteristicsMost cancer survivorsMedical Expenditure Panel SurveyQuality of lifePoor mental healthMyeloproliferative neoplasms (MPNs) have a significant impact on patients’ overall health and productivity: the MPN Landmark survey
Mesa R, Miller CB, Thyne M, Mangan J, Goldberger S, Fazal S, Ma X, Wilson W, Paranagama DC, Dubinski DG, Boyle J, Mascarenhas JO. Myeloproliferative neoplasms (MPNs) have a significant impact on patients’ overall health and productivity: the MPN Landmark survey. BMC Cancer 2016, 16: 167. PMID: 26922064, PMCID: PMC4769833, DOI: 10.1186/s12885-016-2208-2.Peer-Reviewed Original ResearchConceptsPrognostic risk scoreMyeloproliferative neoplasmsRisk scorePolycythemia veraEssential thrombocythemiaDisease burdenDaily livingOverall healthSymptom severityMedian disease durationLandmark surveyPatient's overall healthOverall disease burdenRisk of mortalityMedian respondent ageLower symptom severityDisease durationSymptom burdenPatients' qualityMPN subtypesTreatment managementPatientsConclusionsThese findingsResultsThe surveyQoL